Tom Beer, M.D.
Consulting
Dr. Tomasz M. (Tom) Beer serves or has served on Advisory Boards for Cancer Centers, programs, organizations, biopharmaceutical companies, and international clinical trials. He advised early stage biotechnology companies and large pharmaceutical companies on clinical development strategy for oncology drug candidates.
Dr. Beer provided advice and expert opinion on standards of care, best practices, scientific evidence, clinical decision making and outcomes in support of litigation and offered advice and analysis regarding current and future clinical trends in prostate cancer, risks and opportunities for current and future drug products in support of investment and business decisions.
Selected Examples:
ZERO – The End of Prostate Cancer (2013-present)
Serves on the Medical Advisory Board. Provides strategic guidance and direction for research investment and educational resources and programs
Salarius Pharmaceuticals LLC (2014-present)
Serves on the Scientific Advisory Board in support of the development of a small molecule LSD1 inhibitor. In 2016, Salarius received a $18.69 million New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT) and in 2018 received FDA approval to initiate human trials. In early 2019, Flex Pharma and Salarius Pharmaceuticals announced a merger agreement
Astra Zeneca (2016-present)
Serves as Chair of the Independent Data Safety Monitoring Committee Study for the Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROFound Trial)
Serves as Chair of the Independent Data Safety Monitoring Committee Study for the PROpel Trial (2018-present)
Arvinas, Inc. (2019-present)
Serves on the Company Scientific Advisory Board focusing on advising the company on clinical development in cancer indications
PATCH: Prostate cancer Analysis for Therapy CHoice (2019-2022)
Serves as member of the Scientific Advisory Committee
Pelican Therapeutics, Inc. (2014-2017)
Member of the Scientific Advisory Board in support of clinical development of strategies to target the co-stimulatory receptor TNFRSF25 as cancer immunotherapy. In 2016, Pelican successfully competed for a $15.2 million New Company Product Development Award from CPRIT
Tisch Cancer Institute at Mount Sinai - Icahn School of Medicine, NY (2015)
Served as Ad Hoc member on the External Advisory Board that supported the Institute in its successful application to become an NCI designated Cancer Center in 2015
Dr. Beer provided advice and expert opinion on standards of care, best practices, scientific evidence, clinical decision making and outcomes in support of litigation and offered advice and analysis regarding current and future clinical trends in prostate cancer, risks and opportunities for current and future drug products in support of investment and business decisions.
Selected Examples:
ZERO – The End of Prostate Cancer (2013-present)
Serves on the Medical Advisory Board. Provides strategic guidance and direction for research investment and educational resources and programs
Salarius Pharmaceuticals LLC (2014-present)
Serves on the Scientific Advisory Board in support of the development of a small molecule LSD1 inhibitor. In 2016, Salarius received a $18.69 million New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT) and in 2018 received FDA approval to initiate human trials. In early 2019, Flex Pharma and Salarius Pharmaceuticals announced a merger agreement
Astra Zeneca (2016-present)
Serves as Chair of the Independent Data Safety Monitoring Committee Study for the Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROFound Trial)
Serves as Chair of the Independent Data Safety Monitoring Committee Study for the PROpel Trial (2018-present)
Arvinas, Inc. (2019-present)
Serves on the Company Scientific Advisory Board focusing on advising the company on clinical development in cancer indications
PATCH: Prostate cancer Analysis for Therapy CHoice (2019-2022)
Serves as member of the Scientific Advisory Committee
Pelican Therapeutics, Inc. (2014-2017)
Member of the Scientific Advisory Board in support of clinical development of strategies to target the co-stimulatory receptor TNFRSF25 as cancer immunotherapy. In 2016, Pelican successfully competed for a $15.2 million New Company Product Development Award from CPRIT
Tisch Cancer Institute at Mount Sinai - Icahn School of Medicine, NY (2015)
Served as Ad Hoc member on the External Advisory Board that supported the Institute in its successful application to become an NCI designated Cancer Center in 2015
Healthcare Executive Experience
As Deputy Director of the OHSU Knight Cancer Institute, Dr. Tomasz M. (Tom) Beer worked in partnership with his hospital counterpart, the VP for Oncology Services, to drive growth and excellence in cancer services with responsibility for a service line that generates over $480 million in gross charges, employs 380 professionals at 7 locations on campus and throughout the Portland metro area. Selected accomplishments:
• Developed a 10-year space program for oncology services that included the building of a new clinical tower and ambulatory hospital building scheduled for delivery in 2019.
• Achieved in-patient market share growth of 5% in a shrinking in-patient Portland metro market while also growing ambulatory visits with an improved contribution margin of $77M.
• Through a joint operating agreement, developed and implemented an Academic/Community partnership, OHSU Knight-Legacy Health Cancer Collaboration, providing OHSU Knight branded hematology/oncology, infusion and radiation oncology services to a major community hospital system in the Portland metro region.
• Added a new business arrangement with The Vancouver Clinic in Vancouver, WA that expanded the collaboration to 2 additional sites in 2017.
• Successfully competed to participate and implement the Oncology Care Model (OCM), the CMMI pilot project to redesign oncology care delivery and financing moving towards paying for value not volume. OHSU Knight is one of 6 academic centers chosen for this pilot project.
• Selected and oversaw the development and implementation of the Knight Pathways powered by Via Oncology. This is a clinical decision support tool customized for Knight Cancer Institute providers incorporating the latest in personalized medicine and clinical trials and deployed across the OHSU Knight Cancer Network achieving network wide standardization of care.
• Developed a 10-year space program for oncology services that included the building of a new clinical tower and ambulatory hospital building scheduled for delivery in 2019.
• Achieved in-patient market share growth of 5% in a shrinking in-patient Portland metro market while also growing ambulatory visits with an improved contribution margin of $77M.
• Through a joint operating agreement, developed and implemented an Academic/Community partnership, OHSU Knight-Legacy Health Cancer Collaboration, providing OHSU Knight branded hematology/oncology, infusion and radiation oncology services to a major community hospital system in the Portland metro region.
• Added a new business arrangement with The Vancouver Clinic in Vancouver, WA that expanded the collaboration to 2 additional sites in 2017.
• Successfully competed to participate and implement the Oncology Care Model (OCM), the CMMI pilot project to redesign oncology care delivery and financing moving towards paying for value not volume. OHSU Knight is one of 6 academic centers chosen for this pilot project.
• Selected and oversaw the development and implementation of the Knight Pathways powered by Via Oncology. This is a clinical decision support tool customized for Knight Cancer Institute providers incorporating the latest in personalized medicine and clinical trials and deployed across the OHSU Knight Cancer Network achieving network wide standardization of care.